Pfizer (NYSE: PFE) details Q4 2025 financial results in furnished press release

Rhea-AI Filing Summary

Pfizer Inc. filed a current report to make investors aware that it has released its financial results for the fourth quarter of 2025. The company did this by issuing a press release on February 3, 2026, which is attached to the report as Exhibit 99.

The press release is formally provided for information purposes and is not treated as being legally “filed” under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.

0000078003false00000780032026-02-032026-02-030000078003us-gaap:CommonStockMember2026-02-032026-02-030000078003pfe:NotesDue20271.000Member2026-02-032026-02-030000078003pfe:NotesDue20292.875Member2026-02-032026-02-030000078003pfe:NotesDue20323.250Member2026-02-032026-02-030000078003pfe:NotesDue20373.875Member2026-02-032026-02-030000078003pfe:NotesDue20454.250Member2026-02-032026-02-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 3, 2026

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware			1-3619			13-5315170
(State or other			(Commission File			(I.R.S. Employer
jurisdiction of			Number)			Identification No.)
incorporation)

66 Hudson Boulevard East						10001-2192
New York,			New York			(Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code:

(212) 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.05 par value

PFE

New York Stock Exchange

1.000% Notes due 2027

PFE/27

New York Stock Exchange

2.875% Notes due 2029

PFE/29

New York Stock Exchange

3.250% Notes due 2032

PFE/32

New York Stock Exchange

3.875% Notes due 2037

PFE/37A

New York Stock Exchange

4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 2.02 Results of Operations and Financial Condition

On February 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the fourth quarter of 2025. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.

The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)  Exhibits

Exhibit Number						Exhibit Description
Exhibit 99						Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

EXHIBIT INDEX
Exhibit No.						Description
99						Press Release of Pfizer Inc. dated February 3, 2026, reporting Pfizer’s financial results for the fourth quarter of 2025.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PFIZER INC.
			By:			/s/ Margaret M. Madden
						Margaret M. Madden
						Senior Vice President and Corporate Secretary
						Chief Governance Counsel

Dated: February 3, 2026

FAQ

What did Pfizer (PFE) disclose in this 8-K filing?

Pfizer disclosed that it issued a press release announcing its financial results for the fourth quarter of 2025. The press release, dated February 3, 2026, is attached as Exhibit 99 and provides the detailed financial information for that period.

When did Pfizer (PFE) release its Q4 2025 financial results?

Pfizer released its fourth quarter 2025 financial results on February 3, 2026. The company announced these results through a press release, which is included with the report as Exhibit 99 for investors and analysts who want the full details.

How are Pfizer’s Q4 2025 results presented in this 8-K?

Pfizer’s Q4 2025 results are presented through a separate press release furnished as Exhibit 99. The 8-K itself mainly references this exhibit rather than listing detailed numbers directly in the body of the report.

Is Pfizer’s Q4 2025 earnings press release considered “filed” with the SEC?

No. Pfizer specifies that the information under Item 2.02, including Exhibit 99, is “furnished” rather than “filed.” This means it is not subject to certain liability provisions of Section 18 of the Exchange Act under this designation.

What exhibits are included with Pfizer’s 8-K on Q4 2025 results?

The report includes two exhibits: Exhibit 99, which is Pfizer’s press release dated February 3, 2026 reporting fourth quarter 2025 financial results, and Exhibit 104, which contains the Inline XBRL cover page data tags embedded in the electronic version.

Who signed Pfizer’s 8-K related to Q4 2025 results?

The report was signed on behalf of Pfizer Inc. by Margaret M. Madden. She is identified as Senior Vice President, Corporate Secretary, and Chief Governance Counsel, indicating her role in overseeing corporate governance and SEC reporting formalities.